A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab VersusStandard of Care for Participants Previously Treated with Immunotherapy for Stage IVor Recurrent Non-Small Cell Lung Cancer
Study of Ramucirumab Plus Pembrolizumab vs. Standard of Care in Patients with Non-Small Cell Lung Cancer (NSCLC)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU8154
U.S. Govt. ID: NCT05633602
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the drugs ramucirumab and pembrolizumab to standard-of-care treatment in patients whose lung cancer has progressed on immunotherapy. The study doctors hope to learn if the drug combination will help patients with stage IV or recurrent non-small cell lung cancer (NSCLC) live longer. The study is set up to find out if this drug combination is better, the same, or worse than the usual treatment. The usual approach is the care most people get for lung cancer. For patients not in a study, the usual approach is treatment with chemotherapy, which is approved by the Food and Drug Administration (FDA). Combining ramucirumab and pembrolizumab is not approved by the FDA to treat advanced lung cancer.
Stephanie Smith-Marrone, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with non-small cell lung cancer (NSCLC)? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator